Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 19, 2026, 12:41 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 817–840 of 1,097 matching trials from the live ClinicalTrials.gov search.
Conditions
Leukemia, Lymphoma
Interventions
indium In 111 LL2 IgG, yttrium Y 90 epratuzumab
Radiation
Lead sponsor
Garden State Cancer Center at the Center for Molecular Medicine and Immunology
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1998
U.S. locations
2
States / cities
Belleville, New Jersey • Philadelphia, Pennsylvania
Conditions
Hodgkin's Disease, Non Hodgkin's Lymphoma, Myeloma, Leukemia, Myelodysplasia
Interventions
Non-myeloablative Stem Cell Transplantation
Drug
Lead sponsor
David Rizzieri, MD
Other
Eligibility
18 Years and older
Enrollment
264 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
Durham, North Carolina
Conditions
Lymphoma, Lymphoma, B-Cell, Immune System Diseases, Immunoproliferative Disorders, Lymphatic Diseases
Interventions
iC9-CAR19 T cells, Bendamustine, Fludarabine, AP1903, Cyclophosphamide
Biological · Drug
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2040
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Conditions
Primary Immune Thrombocytopenia (ITP), Primary Evans Syndrome (ES)
Interventions
ianalumab, thrombopoietin receptor agonist (TPO-RA)
Biological · Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
164 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
24
States / cities
Chandler, Arizona • Fayetteville, Arkansas • Torrance, California + 21 more
Conditions
Non-Small-Cell Lung
Interventions
Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody, Placebo Comparator, Nab-paclitaxel, Pemetrexed, Carboplatin, Cisplatin, Gemcitabine
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
453 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
24
States / cities
Tucson, Arizona • Los Angeles, California • Orange, California + 18 more
Conditions
Relapsed Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma
Interventions
Ipilimumab, Nivolumab
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
New York, New York
Conditions
Solid Tumor, Microsatellite Stable Colorectal Cancer, HPV Positive Oropharyngeal Squamous Cell Carcinoma, Cervical Cancer, Melanoma (Skin), Cutaneous Squamous Cell Carcinoma, Mesothelioma, Renal Cell Carcinoma, Oropharynx Cancer
Interventions
TBio-6517, Pembrolizumab
Biological
Lead sponsor
Turnstone Biologics, Corp.
Industry
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
8
States / cities
Phoenix, Arizona • Jacksonville, Florida • Miami, Florida + 5 more
Conditions
SCID
Interventions
Humanized anti-CD117 Monoclonal Antibody (JSP191)
Biological
Lead sponsor
Jasper Therapeutics, Inc.
Industry
Eligibility
3 Months to 12 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
9
States / cities
Los Angeles, California • Palo Alto, California • San Francisco, California + 6 more
Conditions
Large B Cell Lymphoma
Interventions
rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone, etoposide, filgrastim, pegfilgrastim
Biological · Drug
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
524 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2021
U.S. locations
47
States / cities
La Jolla, California • Mountain View, California • Palo Alto, California + 38 more
Conditions
B Cell Leukemia, B Cell Lymphoma
Interventions
CART-19
Biological
Lead sponsor
University of Pennsylvania
Other
Eligibility
1 Year to 24 Years
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2019
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
CD 19+ Acute Leukemia
Interventions
T-cell Antigen Presenting Cells expressing truncated CD19 (T-APC)
Biological
Lead sponsor
Seattle Children's Hospital
Other
Eligibility
1 Year to 30 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2033
U.S. locations
1
States / cities
Seattle, Washington
Conditions
Mild Alzheimer's Disease
Interventions
Allogeneic MSC, Placebo
Drug · Other
Lead sponsor
Longeveron Inc.
Industry
Eligibility
60 Years to 85 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
13
States / cities
Aventura, Florida • Delray Beach, Florida • Doral, Florida + 3 more
Conditions
Mucopolysaccharidosis I, Mucopolysaccharidosis VI, Adrenoleukodystrophy, Niemann-Pick Disease, Metachromatic Leukodystrophy, Wolman Disease, Krabbe's Disease, Gaucher's Disease, Fucosidosis, Batten Disease, Severe Aplastic Anemia, Diamond-Blackfan Anemia, Amegakaryocytic Thrombocytopenia, Myelodysplastic Syndrome, Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia
Interventions
Human Placental Derived Stem Cell
Drug
Lead sponsor
New York Medical College
Other
Eligibility
0 Years to 55 Years
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2022
U.S. locations
3
States / cities
Denver, Colorado • Valhalla, New York • Salt Lake City, Utah
Conditions
Relapsed Diffuse Large B-cell Lymphoma, Refractory Diffuse Large B-cell Lymphoma
Interventions
DPX-Survivac, Pembrolizumab, CPA
Drug
Lead sponsor
ImmunoVaccine Technologies, Inc. (IMV Inc.)
Industry
Eligibility
18 Years and older
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
17
States / cities
Fountain Valley, California • Boca Raton, Florida • Hollywood, Florida + 13 more
Conditions
Carcinoma, Renal Cell, Advanced Renal Cell Carcinoma, Renal Cancer, Renal Neoplasm, Clear Cell Renal Cell Carcinoma, Metastatic Renal Cell Carcinoma, Clear-cell Metastatic Renal Cell Carcinoma, Carcinoma, Renal Cell Metastasis, Advanced or Metastatic Renal Cell Carcinoma, Carcinoma, Renal Cell, Advanced, Metastatic Renal Cell Cancer, Metastatic Renal Cell Carcinoma ( mRCC), Metastatic/Advanced Renal Cell Carcinoma
Interventions
PF-08634404, Ipilimumab, Axitinib, Casdatifan
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
224 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
160
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Fayetteville, Arkansas + 101 more
Conditions
Primary Immune Thrombocytopenia (ITP)
Interventions
Ianalumab, Placebo, Corticosteroids
Biological · Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
226 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
14
States / cities
Yuma, Arizona • Clovis, California • Fountain Valley, California + 10 more
Conditions
Hypogammaglobulinemia, Autoimmune Conditions, Rheumatic Conditions, Infections
Interventions
Panzyga, 10% Intravenous Solution, Placebo
Drug · Other
Lead sponsor
Octapharma
Industry
Eligibility
18 Years and older
Enrollment
360 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
8
States / cities
Glendale, Arizona • Mesa, Arizona • Scottsdale, Arizona + 5 more
Conditions
Advanced Solid Tumors
Interventions
REGN7075, Cemiplimab, Platinum-based doublet chemotherapy, Bevacizumab, Trifluridine-tipiracil
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
548 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
20
States / cities
Los Angeles, California • San Francisco, California • Aurora, Colorado + 15 more
Conditions
Carcinoma, Merkel Cell
Interventions
Avelumab
Drug
Lead sponsor
EMD Serono Research & Development Institute, Inc.
Industry
Eligibility
18 Years and older
Enrollment
204 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2023
U.S. locations
14
States / cities
Los Angeles, California • Aurora, Colorado • Tampa, Florida + 9 more
Conditions
Hodgkin Disease, Lymphoma, Non-Hodgkin, Lymphoma, B-Cell
Interventions
pembrolizumab, Favezelimab
Biological
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
137 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
8
States / cities
Gilbert, Arizona • Duarte, California • Los Angeles, California + 5 more
Conditions
B-Cell Acute Lymphoblastic Leukaemia, ALL, Adult, B-ALL
Interventions
Blinatumomab, Haplo-Mismatched Cell Therapy (HMCT)
Drug · Other
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Los Angeles, California
Conditions
Peripheral T-Cell Lymphoma
Interventions
Brentuximab vedotin
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Tampa, Florida
Conditions
Leukemia, Lymphoma
Interventions
T-Cell Infusion, Cord Blood Infusion
Genetic · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
1 Year to 75 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
Houston, Texas
Conditions
Alzheimer's Disease
Interventions
Longeveron Mesenchymal Stem Cells, Placebo
Biological
Lead sponsor
Longeveron Inc.
Industry
Eligibility
50 Years to 80 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
3
States / cities
Delray Beach, Florida • Miami, Florida